Hybridoma Technology
Introduction
Increased research and accumulation of knowledge in the fields of somatic cell genetics, tissue culture technology and immunology resulted in the development of a technique for in vitro production of antibodies.

The construction of antibody secreting cell lines-hybridomas are produced by fusing antibody secreting lymphocytes with appropriate tumour cell lines – myelonas.

Monoclonal antibody (MAbs) are the first products to move rapidly from the research laboratories through industry to the market place.

MAbs will find use chiefly as research reagents, diagnostics in vitro and in vivo, as the therapeutic agents and in the purification process and vaccine production.